Washington, DC - A secondary analysis of the Hemodialysis (HEMO) Study highlights the significant biases in trial results that can occur when as-treated vs intention-to-treat methodology is applied [ ...
LONDON, UK / ACCESSWIRE / November 18, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, is pleased to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results